Company Announcement no. 10/2011



To: NASDAQ OMX Copenhagen A/S
Hørsholm, Denmark, July 7, 2011



LifeCycle Pharma A/S Passing of Extraordinary General Meeting - Change of
Company Name to Veloxis Pharmaceuticals A/S and Election of new Board Member


Summary: At the Extraordinary General Meeting held earlier today all proposals
made by the Board of Directors were adopted.


At the general meeting, Ed Penhoet was elected as new member of the Board of
Directors for a period ending at the next Annual General Meeting of the
company.


The Board of Directors will hereafter comprise:


Kim Bjørnstrup (Chairman)

Thomas Dyrberg (Deputy Chairman)

Kurt Anker Nielsen

Anders Götzsche

Mette Kirstine Agger

Ed Penhoet


The proposal made by the Board of Directors to change the name of the company
from LifeCycle Pharma A/S to Veloxis Pharmaceuticals A/S and to amend the
Articles of Association accordingly was approved. LifeCycle Pharma A/S shall
hereafter be the company's secondary name.


The proposal made by the Board of Directors to amend the Articles of
Association Article 11 in accordance with the previous resolution to use
electronic communication was adopted.


The chairman of the meeting was, with a right of substitution, authorized to
register resolutions passed by the general meeting with the Danish Commerce and
Companies Agency and to make such alterations as the Agency may require for
registration or approval.



For more information, please contact:



Veloxis Pharmaceuticals A/S Anja Leschly
John Weinberg, M.D. VP, Human Resources and
SVP, Commercial Operations & Investor Communication
Relations Phone: + 45 2055 3818
Phone: +1 908 304 3389 Email: [email protected]
Email: [email protected]

About Veloxis Pharmaceuticals

Veloxis is a specialty pharmaceutical company. Clinical development is the core
of our efforts to develop a product portfolio which includes the Company's lead
product candidate, LCP‐Tacro™, for immunosuppression, specifically organ
transplantation, and products to combat certain cardiovascular diseases.
Veloxis adapts new technologies on a fast commercial timetable. Veloxis'
unique, patented delivery technology, MeltDose®, can improve absorption and
bioavailability ‐ at low‐scale up costs ‐ not only for a broad spectrum of
drugs already on the market but also for new chemical entities. Veloxis has a
lipid lowering product, Fenoglide®, currently on the U.S. market and a
diversified near and medium term pipeline with three clinical stage product
candidates and a number of projects in preclinical development. Veloxis is
listed on the NASDAQ OMX Copenhagen under the trading symbol OMX: VELO.


For further information, please visit www.veloxis.com.

070711 Veloxis Passing of Extraordinary General Meeting.pdf